Identification of prognostic and predictive biomarkers of overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with docetaxel, prednisone (DP) +/- bevacizumab (B) in CALGB 90401 (Alliance)
- Citation:
- J Clin Oncol vol 39 (6_suppl) 154
- Meeting Instance:
- ASCO GU 2021
- Year:
- 2021
- Type:
- Abstract
- Sub type:
- Poster General
- Funding:
- NCTN
- Endpoint:
- Secondary-not-in-original
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- epreprint
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Parents:
- None
- Children:
- 3697
- Pharmas:
- Genentech
- Grants:
- U10CA180821, U10CA180882; DOD grant W81XWH-18-1-0278; U24CA196171
- Corr. Author:
- Authors:
- S Halabi Q. Yang Mark D Starr John C Brady A.J. Armstrong D. George WK Kelly H Beltran M. Morris AB Nixon
- Networks:
- LAPS-MA036, LAPS-NC010, LAPS-NY016
- Study
- CALGB-90401
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 3
- Keywords: